Literature DB >> 25981618

Evaluation of spin freezing versus conventional freezing as part of a continuous pharmaceutical freeze-drying concept for unit doses.

L De Meyer1, P-J Van Bockstal2, J Corver3, C Vervaet4, J P Remon4, T De Beer2.   

Abstract

Spin-freezing as alternative freezing approach was evaluated as part of an innovative continuous pharmaceutical freeze-drying concept for unit doses. The aim of this paper was to compare the sublimation rate of spin-frozen vials versus traditionally frozen vials in a batch freeze-dryer, and its impact on total drying time. Five different formulations, each having a different dry cake resistance, were tested. After freezing, the traditionally frozen vials were placed on the shelves while the spin-frozen vials were placed in aluminum vial holders providing radial energy supply during drying. Different primary drying conditions and chamber pressures were evaluated. After 2h of primary drying, the amount of sublimed ice was determined in each vial. Each formulation was monitored in-line using NIR spectroscopy during drying to determine the sublimation endpoint and the influence of drying conditions upon total drying time. For all tested formulations and applied freeze-drying conditions, there was a significant higher sublimation rate in the spin-frozen vials. This can be explained by the larger product surface and the lower importance of product resistance because of the much thinner product layers in the spin frozen vials. The in-line NIR measurements allowed evaluating the influence of applied drying conditions on the drying trajectories.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous freeze drying; Freeze-drying; NIR spectroscopy; Spin freezing

Mesh:

Substances:

Year:  2015        PMID: 25981618     DOI: 10.1016/j.ijpharm.2015.05.025

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Pharmaceutical protein solids: Drying technology, solid-state characterization and stability.

Authors:  Yuan Chen; Tarun Tejasvi Mutukuri; Nathan E Wilson; Qi Tony Zhou
Journal:  Adv Drug Deliv Rev       Date:  2021-03-08       Impact factor: 15.470

Review 2.  The longstanding challenge of the nanocrystallization of 1,3,5-trinitroperhydro-1,3,5-triazine (RDX).

Authors:  Florent Pessina; Denis Spitzer
Journal:  Beilstein J Nanotechnol       Date:  2017-02-17       Impact factor: 3.649

3.  Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: the Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave.

Authors:  Akhilesh Bhambhani; Justin Stanbro; Daniel Roth; Elizabeth Sullivan; Morrisa Jones; Robert Evans; Jeffrey Blue
Journal:  AAPS PharmSciTech       Date:  2021-01-19       Impact factor: 3.246

4.  Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.

Authors:  Khaled AboulFotouh; Zhengrong Cui; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2021-04-09       Impact factor: 3.246

5.  Development and Application of a Mechanistic Cooling and Freezing Model of the Spin Freezing Step within the Framework of Continuous Freeze-Drying.

Authors:  Gust Nuytten; Susan Ríos Revatta; Pieter-Jan Van Bockstal; Ashish Kumar; Joris Lammens; Laurens Leys; Brecht Vanbillemont; Jos Corver; Chris Vervaet; Thomas De Beer
Journal:  Pharmaceutics       Date:  2021-12-03       Impact factor: 6.321

6.  A NIR-Based Study of Desorption Kinetics during Continuous Spin Freeze-Drying.

Authors:  Laurens Leys; Gust Nuytten; Joris Lammens; Pieter-Jan Van Bockstal; Jos Corver; Chris Vervaet; Thomas De Beer
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

7.  Spin Freezing and Its Impact on Pore Size, Tortuosity and Solid State.

Authors:  Joris Lammens; Niloofar Moazami Goudarzi; Laurens Leys; Gust Nuytten; Pieter-Jan Van Bockstal; Chris Vervaet; Matthieu N Boone; Thomas De Beer
Journal:  Pharmaceutics       Date:  2021-12-09       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.